Kenneth V Lieberman1, Alexander R Chang2, Geoffrey A Block3, Kristina Robinson4, Sara L Bristow4,5, Ana Morales4,5, Asia Mitchell4,5, Stephen McCalley6, Jim McKay6, Martin R Pollak7, Swaroop Aradhya4,5, Bradley A Warady8. 1. Division of Pediatric Nephrology, Joseph M. Sanzari Children's Hospital of the Hackensack Meridian Health Network, Hackensack, New Jersey. 2. Division of Nephrology, Geisinger Medical Center, Danville, Pennsylvania. 3. Division of Clinical Research, Reata Pharmaceuticals, Inc., Plano, Texas. 4. Department of Clinical Genomics, Invitae, San Francisco, California. 5. Department of Medical Affairs, Invitae, San Francisco, California. 6. Division of Medical Affairs, Reata Pharmaceuticals, Inc., Plano, Texas. 7. Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 8. Division of Pediatric Nephrology, Children's Mercy Kansas City, Kansas City, Missouri.
Abstract
Background: Despite increasing recognition that CKD may have underlyi ng genetic causes, genetic testing remains limited. This study evaluated the diagnostic yield and phenotypic spectrum of CKD in individuals tested through the KIDNEYCODE sponsored genetic testing program. Methods: Unrelated individuals who received panel testing (17 genes) through the KIDNEYCODE sponsored genetic testing program were included. Individuals had to meet at least one of the following eligibility criteria: eGFR ≤90 ml/min per 1.73m2 and hematuria or a family history of kidney disease; or suspected/biopsy-confirmed Alport syndrome or FSGS in tested individuals or relatives. Results: Among 859 individuals, 234 (27%) had molecular diagnoses in genes associated with Alport syndrome (n=209), FSGS (n=12), polycystic kidney disease (n=6), and other disorders (n=8). Among those with positive findings in a COL4A gene, the majority were in COL4A5 (n=157, 72 hemizygous male and 85 heterozygous female individuals). A positive family history of CKD, regardless of whether clinical features were reported, was more predictive of a positive finding than was the presence of clinical features alone. For the 248 individuals who had kidney biopsies, a molecular diagnosis was returned for 49 individuals (20%). Most (n=41) individuals had a molecular diagnosis in a COL4A gene, 25 of whom had a previous Alport syndrome clinical diagnosis, and the remaining 16 had previous clinical diagnoses including FSGS (n=2), thin basement membrane disease (n=9), and hematuria (n=1). In total, 491 individuals had a previous clinical diagnosis, 148 (30%) of whom received a molecular diagnosis, the majority (89%, n=131) of which were concordant. Conclusions: Although skewed to identify individuals with Alport syndrome, these findings support the need to improve access to genetic testing for patients with CKD-particularly in the context of family history of kidney disease, hematuria, and hearing loss.
Background: Despite increasing recognition that CKD may have underlyi ng genetic causes, genetic testing remains limited. This study evaluated the diagnostic yield and phenotypic spectrum of CKD in individuals tested through the KIDNEYCODE sponsored genetic testing program. Methods: Unrelated individuals who received panel testing (17 genes) through the KIDNEYCODE sponsored genetic testing program were included. Individuals had to meet at least one of the following eligibility criteria: eGFR ≤90 ml/min per 1.73m2 and hematuria or a family history of kidney disease; or suspected/biopsy-confirmed Alport syndrome or FSGS in tested individuals or relatives. Results: Among 859 individuals, 234 (27%) had molecular diagnoses in genes associated with Alport syndrome (n=209), FSGS (n=12), polycystic kidney disease (n=6), and other disorders (n=8). Among those with positive findings in a COL4A gene, the majority were in COL4A5 (n=157, 72 hemizygous male and 85 heterozygous female individuals). A positive family history of CKD, regardless of whether clinical features were reported, was more predictive of a positive finding than was the presence of clinical features alone. For the 248 individuals who had kidney biopsies, a molecular diagnosis was returned for 49 individuals (20%). Most (n=41) individuals had a molecular diagnosis in a COL4A gene, 25 of whom had a previous Alport syndrome clinical diagnosis, and the remaining 16 had previous clinical diagnoses including FSGS (n=2), thin basement membrane disease (n=9), and hematuria (n=1). In total, 491 individuals had a previous clinical diagnosis, 148 (30%) of whom received a molecular diagnosis, the majority (89%, n=131) of which were concordant. Conclusions: Although skewed to identify individuals with Alport syndrome, these findings support the need to improve access to genetic testing for patients with CKD-particularly in the context of family history of kidney disease, hematuria, and hearing loss.
Authors: Natasha T Strande; Erin Rooney Riggs; Adam H Buchanan; Ozge Ceyhan-Birsoy; Marina DiStefano; Selina S Dwight; Jenny Goldstein; Rajarshi Ghosh; Bryce A Seifert; Tam P Sneddon; Matt W Wright; Laura V Milko; J Michael Cherry; Monica A Giovanni; Michael F Murray; Julianne M O'Daniel; Erin M Ramos; Avni B Santani; Alan F Scott; Sharon E Plon; Heidi L Rehm; Christa L Martin; Jonathan S Berg Journal: Am J Hum Genet Date: 2017-05-25 Impact factor: 11.025
Authors: Moumita Barua; Emilia Stellacci; Lorenzo Stella; Astrid Weins; Giulio Genovese; Valentina Muto; Viviana Caputo; Hakan R Toka; Victoria T Charoonratana; Marco Tartaglia; Martin R Pollak Journal: J Am Soc Nephrol Date: 2014-03-27 Impact factor: 10.121
Authors: Morgan E Grams; Stephen P Juraschek; Elizabeth Selvin; Meredith C Foster; Lesley A Inker; John H Eckfeldt; Andrew S Levey; Josef Coresh Journal: Am J Kidney Dis Date: 2013-04-22 Impact factor: 8.860
Authors: Nathan R Hill; Samuel T Fatoba; Jason L Oke; Jennifer A Hirst; Christopher A O'Callaghan; Daniel S Lasserson; F D Richard Hobbs Journal: PLoS One Date: 2016-07-06 Impact factor: 3.240
Authors: Katherine A Benson; Susan L Murray; Ross Doyle; Brendan Doyle; Anthony M Dorman; Denise Sadlier; Eoin Brennan; Margaret Large; Gianpiero L Cavalleri; Catherine Godson; Peter J Conlon Journal: Cold Spring Harb Mol Case Stud Date: 2020-10-07
Authors: Rebecca Truty; Joshua Paul; Michael Kennemer; Stephen E Lincoln; Eric Olivares; Robert L Nussbaum; Swaroop Aradhya Journal: Genet Med Date: 2018-06-12 Impact factor: 8.822
Authors: Christie P Thomas; Margaret E Freese; Agnes Ounda; Jennifer G Jetton; Myrl Holida; Lama Noureddine; Richard J Smith Journal: Genet Med Date: 2021-10 Impact factor: 8.822